These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 11739446)

  • 1. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
    Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
    Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
    Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
    Uto Y; Teno S; Iwamoto Y; Omori Y; Takizawa T
    Metabolism; 2002 Jan; 51(1):20-4. PubMed ID: 11782867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
    Mori Y; Kitahara Y; Miura K; Mine T; Tajima N
    Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.
    Fonseca VA; Kelley DE; Cefalu W; Baron MA; Purkayastha D; Nestler JE; Hsia S; Gerich JE
    Metabolism; 2004 Oct; 53(10):1331-5. PubMed ID: 15375790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of first phase insulin secretion by a nateglinide-intravenous glucose insulin release test in newly diagnosed type 2 diabetics].
    Luo GC; Liang Z; Hu QH; Chai J; Li MZ; Yan DW; Li HY
    Zhonghua Nei Ke Za Zhi; 2006 Aug; 45(8):646-9. PubMed ID: 17074149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.
    Johanson EH; Jansson PA; Gustafson B; Sandqvist M; Taskinen MR; Smith U; Axelsen M
    Diabetes Metab Res Rev; 2005; 21(4):376-81. PubMed ID: 15724236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
    Hirose T; Mizuno R; Yoshimoto T
    Endocr J; 2002 Dec; 49(6):649-52. PubMed ID: 12625415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
    Hu S
    Eur J Pharmacol; 2002 May; 442(1-2):163-71. PubMed ID: 12020694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats.
    Mori Y; Ojima K; Fuujimori Y; Aoyagi I; Kusama H; Yamazaki Y; Kojima M; Shibata N; Itoh Y; Tajima N
    Endocrine; 2006 Apr; 29(2):309-15. PubMed ID: 16785606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.
    Lindsay JR; McKillop AM; Mooney MH; O'Harte FP; Flatt PR; Bell PM
    Diabetes Res Clin Pract; 2003 Sep; 61(3):167-73. PubMed ID: 12965106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
    Kalbag JB; Walter YH; Nedelman JR; McLeod JF
    Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.
    Whitelaw DC; Clark PM; Smith JM; Nattrass M
    Diabet Med; 2000 Mar; 17(3):225-9. PubMed ID: 10784228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
    McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
    Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early insulin release effectively improves glucose tolerance: studies in two rodent models of type 2 diabetes mellitus.
    de Souza CJ; Gagen K; Chen W; Dragonas N
    Diabetes Obes Metab; 2001 Apr; 3(2):85-95. PubMed ID: 11298730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
    Luzio SD; Anderson DM; Owens DR
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
    Courtois P; Jijakli H; Ladriere L; Oguzhan B; Sener A; Malaisse WJ
    Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.